The company said revenue for Q3 2024 rose to $2,289 million, up 6% from $2,166 million a year earlier, and adjusted operating income increased 18% to $414 million.

1. 01

   The company said revenue for Q3 2024 rose to $2,289 million, up 6% from $2,166 million a year earlier, and adjusted operating income increased 18% to $414 million.

2. 02

   WTW said it posted a net loss of $1.67 billion for Q3 2024, compared with net income of $139 million a year earlier. It said the operating loss, net loss and diluted EPS each included pre-tax non-cash losses and impairment charges of over $1.0 billion related to the pending sale of TRANZACT.

3. 03

   The company said revenue in its Health, Wealth & Career segment for Q3 was $1,328 million (organic 4%), with an operating margin of 24.7%, while Risk & Broking revenue was $940 million (organic 10%), with an operating margin of 18.1%.

4. 04

   WTW said operating cash flow for the 9 months was $913 million and free cash flow was $807 million, and it repurchased $205 million of its outstanding shares in Q3. It also set its full-year 2024 adjusted diluted EPS target at $16.00 to $17.00.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.